// App-Quantinova.ai

521 : AK112, a tetravalent bispecific antibody targeting PD-1 and VEGF, enhances binding avidity and functional activities and elicits potent anti-tumor efficacy in pre-clinical studies

Researchers

Presenter

  • Tingting Zhong

Principal Investigators

  • Zhaoliang Huang

  • Xinghua Pang

  • Chunshan Jin

  • Xinrong He

  • Yu Xia

  • Baiyong Li

  • Jing Min

Medical Centers

  • N/A

Locations

  • China

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • Programmed cell death protein 1

  • Programmed death-ligand 1

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved